Effects of pindolol on serum lipoproteins and postheparin lipolytic activities in hypertensive patients

Clin Ther. 1990 Mar-Apr;12(2):157-64.

Abstract

Thirty-four hyperlipoproteinemic, hypertensive patients received 5 mg of pindolol twice daily for 12 weeks. During pindolol administration, there were significant decreases in serum triglyceride levels and increases in high-density lipoprotein cholesterol (HDL-C) levels, while total cholesterol levels did not change. Serum levels of very-low-density lipoprotein (VLDL) triglyceride and VLDL cholesterol decreased over time as HDL-C increased. There was a significant increase in low-density lipoprotein cholesterol at week 12. Apolipoprotein (apo) A-I, A-II, and B levels did not change during pindolol administration, but apo C-II, C-III, and E levels decreased significantly. Lipoprotein lipase activity in heparin-treated plasma was significantly higher after pindolol administration. The results suggest that the reduction in triglyceride levels and increase in HDL-C after pindolol are partly a response to an increase in the hydrolysis of VLDL resulting from an increase in lipoprotein lipase activity.

MeSH terms

  • Apolipoproteins / blood
  • Blood Pressure / drug effects
  • Cholesterol, HDL / blood
  • Cholesterol, VLDL / blood
  • Heparin / pharmacology*
  • Humans
  • Hyperlipoproteinemias / blood
  • Hypertension / blood*
  • Hypertension / physiopathology
  • Lipids / blood
  • Lipolysis / drug effects*
  • Lipoproteins / blood*
  • Pindolol / pharmacology*
  • Triglycerides / blood

Substances

  • Apolipoproteins
  • Cholesterol, HDL
  • Cholesterol, VLDL
  • Lipids
  • Lipoproteins
  • Triglycerides
  • Heparin
  • Pindolol